Genelux Investor Presentation Deck

Olvi-Vec Demonstrates Monotherapy Oncolysis and Immune Activation Key Takeaways Olvi-Vec monotherapy shows decreased tumor cells and increase immune activation Olvi-Vec treatment was able to dramatically decrease or eliminate tumor cells in multiple patient samples The Activation of Immunosurveillance by Olvi-Vec after 2 doses was seen in multiple cavities as monotherapy GENELUX Olvi-Vec Treatment on Days 3 & 4 baseline Clusters of tumor cells Limited immune cells Oncolysis Day 5 ܀ (Pt.#15A-01) Day 10 Drastic reduced tumor cells Large increase of immune cells Immune activation (Pt.#15A-11) Elimination of Cancer Cells after Increased Lymphocyte Infiltration in different cavities peritoneal fluid pleural fluid Prior to 1st dose W2D12 (VIRO-15: monotherapy) W2D17 W2D9 Tumor cell clusters present W2D15 Robust lymphocyte count increase W2D17 Tumor cell clusters absent 35

View entire presentation